This website is intended for healthcare professionals only and contains promotional content.

Report an adverse event here
Link Logo

NOTICE: Kyowa Kirin International has agreed a joint venture with Grünenthal GmbH for the Established Medicines portfolio. The new company, KKI NewCo (known as Grünenthal Meds), is responsible for the content on this page. For more information please click here.​

The effects of opioids on the gut and the limitations of laxatives in the treatment of OIC

In this video, Professor Asbjørn Mohr Drewes talks about the effects of opioids on the gut and the limitations of laxatives in the treatment of OIC. Professor Drewes is a pain medicine specialist and professor of gastroenterology at Aalborg University Hospital. His research interests include: pain therapy, gastroenterology and pharmacology, including the effect of opioids on the gut, the effect of opioid antagonists, and gastrointestinal physiology and imaging.

Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse Events should also be reported to Kyowa Kirin International UK NewCo Ltd, known as Grünenthal Meds on +44 (0)1896 664000, email PVUK@grunenthalmeds.com

MOVENTIG (naloxegol) is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s). For advice on the responsible use of opioids to treat pain, please click here

Average: